Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
Feb 27, 2020
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
Feb 18, 2020
Global ADC Linker & Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience
Feb 18, 2020
Antibody Drug Conjugates (ADCs)-Linker and Conjugation Technologies Market, 2019-2030
Dec 09, 2019
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Nov 14, 2019
FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
Jun 28, 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Feb 13, 2019
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR(TM) Technology Targeting Delivery Directly to the Tumor
Dec 03, 2018
News Tips From NYU School Of Medicine And Perlmutter Cancer Center Researchers At The 60th American Society Of Hematology Meeting, Dec. 1-4, In San Diego, Calif.
Nov 16, 2018
FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
Jun 03, 2018
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
May 15, 2018
Peripheral T-Cell Lymphoma (PTCL) Market Spotlight - Forecast to 2025
Apr 18, 2018
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR(TM) Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
Mar 26, 2018
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 20, 2018
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy
Jan 18, 2018
Critical Hodgkin's Lymphoma cancer study published in the New England Journal of Medicine
Dec 10, 2017
Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies
Nov 08, 2017
Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Oct 10, 2017
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Sep 28, 2017
Antibody Drug Conjugates Market Grow at 21.82% CAGR By 2022, Analysis by Adcetris, Kadcyla and Pipeline Drugs